During the recent session, Bioline Rx Ltd ADR (NASDAQ:BLRX)’s traded shares were 17.98 million, with the beta value of the company hitting 1.13. At the last check today, the stock’s price was $6.29, reflecting an intraday gain of 65.92% or $2.5. The 52-week high for the BLRX share is $35.60, that puts it down -465.98 from that peak though still a striking 63.43% gain since the share price plummeted to a 52-week low of $2.30. The company’s market capitalization is $23.40M, and the average intraday trading volume over the past 10 days was 37910.0 shares, and the average trade volume was 27.47K shares over the past three months.
Bioline Rx Ltd ADR (BLRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. BLRX has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
Bioline Rx Ltd ADR (NASDAQ:BLRX) trade information
Bioline Rx Ltd ADR (BLRX) registered a 65.92% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 65.92% in intraday trading to $6.29, hitting a weekly high. The stock’s 5-day price performance is 65.53%, and it has moved by 81.27% in 30 days. Based on these gigs, the overall price performance for the year is -78.13%. The short interest in Bioline Rx Ltd ADR (NASDAQ:BLRX) is 0.18 million shares and it means that shorts have 10.35 day(s) to cover.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 46.38%. While earnings are projected to return 96.78% in 2025, the next five years will return 76.79% per annum.
BLRX Dividends
Bioline Rx Ltd ADR is due to release its next quarterly earnings on 2024-Nov-24. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Bioline Rx Ltd ADR (NASDAQ:BLRX)’s Major holders
Bioline Rx Ltd ADR insiders own 4.67% of total outstanding shares while institutional holders control 0.25%, with the float percentage being 0.27%. MORGAN STANLEY is the largest shareholder of the company, while 12.0 institutions own stock in it. As of 2024-06-30, the company held over 68437.0 shares (or 0.0857% of all shares), a total value of $39002.0 in shares.
The next largest institutional holding, with 1.95 million shares, is of ALYESKA INVESTMENT GROUP, L.P.’s that is approximately 0.0041% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.11 million.
Data provided on Mar 31, 2025 indicates that Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund owns about 999.0 shares. This amounts to just over 0.03 percent of the company’s overall shares, with a $7142.0 market value.